Surufatinib plus TAS-102 showed promising survival benefits with manageable toxicity in refractory metastatic PDAC patients, ...
Our livers contain many different types of immune cells. New research by the team of Prof. Charlotte Scott (VIB-UGent Center ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback